Products Targeting Alzheimer's, Duchenne & COVID-19 Among New EU Filings

 
• By Neena Brizmohun
Alzheimer's patient
Donanemab was shown to significantly slow cognitive and functional decline in people with early symptomatic Alzheimer's disease • Source: Shutterstock

More from Europe

More from Geography